🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Congrats Dr. Julie Brahmer for receiving the IASLC Paul Bunn Scientific Award at #WCLC2024! Johns Hopkins Thoracic Oncology Johns Hopkins Kimmel Cancer Center Johns Hopkins Medicine

💥 The end of Pembro reign? Phase 3 Study of Ivonescimab (AK112) vs. Pembrolizumab as First-line Treatment for PD-L1-positive Advanced NSCLC: HARMONi-2 #WCLC24 #LCSM

#WCLC24 Presidential I Ph III HARMONI-2 ivonescimab v pembro in PDL>1% NSCLC: - 398pts - PFS HR 0.51 (11.1 v 5.82 mPFS) - benefit across histology & PDL1 🌟 Impressive data overall ❓Is this a step forward for PDL1 1-49% grp? 80% males enrolled, data needed in women IASLC

🔥🚨OncoAlert HOT OFF THE PRESS. Just presented at the presidential symposium IASLC #WCLC24 Results of #HARMONi2 trial of #Ivonescimab VS #Pembrolizumab in advanced non-small cell #LungCancer with PD-L1 >1%. ✅ Significant ⬆️mPFS 11.14 vs. 5.82 months (HR 0.51) #Benefit

Taking in the data at #WCLC24 with Dr. D. Ross Camidge - 10/10 highly recommend

ARTEMIS-001 results at #WCLC24. HS-20093 (B7-H3 ADC) in #SCLC with impressive efficacy. RR 50-61% and DCR 81-96% across two doses. DOR 6.4-8.9m. AES mostly hematologic. 8mg/kg dose seems more favorable. No link with B7H3 expression and efficacy. Phase 3 studies ongoing.

Wonderful to so see so many members & friends of our ALK+ community from all around the world at IASLC #WCLC24!

Thrilled to see my mentor Oscar Arrieta speak at the #WCLC2024 Opening Plenary Session! Truly honored to have been guided by someone who continues to inspire my research and clinical journey. Instituto Nacional de Cancerología #Mexico #LungCancer

At IASLC 2024 celebration

Monday morning at #WCLC24: The second of two Presidential Symposia will showcase late-breaking abstracts on targeted therapies. Learn more from IASLC President Dr. Paul Van Schil in #ILCN: bit.ly/3Ze8hWb #LCSM

Dr. Xiuning Le MD PhD presents data on BAY 2927088 in #HER2 mutant NSCLC from the SOHO-01 study at the #WCLC24 Presidential Plenary. Here: results from cohort D with prior therapy but no prior HER2 directed therapy

Presidential symposium alert IASLC #WCLC2024- taking on the challenging NSCLC with HER2 mutations by its horns with promising targeted therapies

#WCLC24 Presidential II Ph I/II FURTHER trial of Firmonertinib for EGFR PACC mutation+ NSCLC: - 47pts - 2 dose levels 160mg QD, 240mg QD - ORR 63.6%, DCR 100%, 20.7% g3+ tox (240mg dose) - prolonged responses, 91% still on tx d.planchard Gustave Roussy Xiuning Le MD PhD IASLC #LCSM

Extended follow-up of tarlatamab, DeLLphi-301. mDOR: 9.7 months mOS: 15.2 months (note no difference based on chemo-free interval) Cytokine release syndrome (CRS) mostly during cycle 1 Tarlatamab is an important tool for treatment of ES-SCLC #WCLC24

🔥🚨1/2 OncoAlert Hot off the press. Just published Journal of Clinical Oncology in conjunction with presentation of overall survival data IASLC #WCLC2024. Results of #TROPION-Lung01 Study of #Datopotamab Deruxtecan Vs Docetaxel for Previously Treated Advanced #NSCLC. 👇🏼 ascopubs.org/doi/10.1200/JC…

D. Ross Camidge Can confirm!

Seriously, I’m past the glass trophies, I vote for custom sneakers as the real awards to be thankful for…

Welcome #WCLC25 Conference Chairs! Umberto Malapelle Jarushka Naidoo Noemi Reguart Isabelle Opitz IASLC